Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors
January 24 2019 - 7:00AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, has appointed Fred
Cohen, M.D., D.Phil, F.A.C.P., to its board of directors. Dr.
Cohen, a noted veteran of the biotechnology industry with vast
experience across multiple companies, joins Intellia’s board as the
company’s pipeline heads toward clinical development.
“We are honored to have Fred join Intellia’s board of directors.
Fred has experience in the biotech industry that is unsurpassed for
its breadth and depth. He has worked with early-stage companies as
they move to the clinic as well as helped mature, product-based
organizations pursue growth strategies,” said Intellia President
and Chief Executive Officer John Leonard, M.D. “Fred brings deep
insights to realizing the vast potential of genome editing therapy,
both for in vivo and engineered cell approaches, and he will help
Intellia further our strategic goal of building a full-spectrum
genome editing company.”
Dr. Cohen is a founder and senior managing director at Vida
Ventures. Prior to Vida, he founded and was a partner at TPG
Biotechnology, where he served 16 years. Dr. Cohen also was
previously the chief of endocrinology and metabolism and a
professor of cellular and molecular pharmacology, medicine,
biochemistry and biophysics at the University of California, San
Francisco (UCSF).
Elected to the National Academy of Medicine in 2004 and the
American Academy of Arts and Sciences in 2008, Dr. Cohen is
best known as a pioneer in prion diseases, has published over 200
papers and has received multiple
awards. He currently serves on the board of
directors of Genomic Health Inc., CareDx Inc., Veracyte Inc.,
Tandem Diabetes Care Inc. and UroGen Pharmaceuticals LTD, as well
as various other private companies.
Dr. Cohen received his bachelor’s degree in molecular
biophysics and biochemistry from Yale University, his D.Phil. in
molecular biophysics from the University of Oxford on a Rhodes
Scholarship, his doctor of medicine from Stanford University
and his postdoctoral training and postgraduate medical training in
internal medicine and endocrinology at UCSF.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases, or can replace patients’ diseased
cells. The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more
about Intellia Therapeutics and CRISPR/Cas9
at intelliatx.com and follow us on Twitter
@intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements” of
Intellia Therapeutics, Inc. (“Intellia”) within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express
or implied statements regarding Intellia’s ability to advance and
expand the CRISPR/Cas9 technology to develop into human therapeutic
products, as well as our CRISPR/Cas9 intellectual property
portfolio; our ability to achieve stable or effective genome
editing; the timing and potential achievement of milestones to
advance our pipeline; and our growth as a company and the
anticipated contribution of the members of our board of directors
and our executives to our operations and progress.
Any forward-looking statements in this presentation are based on
management’s current expectations and beliefs of future events, and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: risks related to
Intellia’s ability to protect and maintain our intellectual
property position; risks related to the ability of our licensors to
protect and maintain their intellectual property position;
uncertainties related to the initiation and conduct of studies and
other development requirements for our product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed and commercialized; the risk that the
results of preclinical studies will not be predictive of future
results in connection with future studies; the risk that Intellia’s
collaborations with Novartis or Regeneron or its
other ex vivo collaborations will not continue or will not be
successful; and risks related to the competitive landscape. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K and quarterly reports on
Form 10-Q filed with the Securities and Exchange Commission,
as well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with
the Securities and Exchange Commission. All information in
this presentation is as of the date of the release,
and Intellia Therapeutics undertakes no duty to update
this information unless required by law.
Intellia Contacts:
Media:Jennifer Mound SmoterSenior Vice
PresidentExternal Affairs & Communications+1
857-706-1071jenn.smoter@intelliatx.com
Lynnea OlivarezAssociate DirectorExternal Affairs &
Communications+1 956-330-1917lynnea.olivarez@intelliatx.com
Investors:Lindsey TrickettVice
PresidentInvestor Relations+1
857-285-6211lindsey.trickett@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Oct 2023 to Oct 2024